1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Latvia Pharmaceuticals and Healthcare Report Q4 2015

Latvia Pharmaceuticals and Healthcare Report Q4 2015

  • August 2015
  • -
  • Business Monitor International
  • -
  • 104 pages

Includes 3 FREE quarterly updates

BMI View: The development of Latvia's market will be shaped by an increased emphasis on generic drugs;
an implication of fiscal austerity measures. As a result, despite its transparent regulatory policies and business-friendly operating environment, the Latvian pharmaceutical market will continue to remain a modest prospect for drugmakers.

Headline Expenditure Projections

- Pharmaceuticals: EUR319mn (USD428mn) in 2014 to EUR338mn (USD372mn) in 2015; +5.8% in local currency terms and -13.2% in US dollar terms. Forecast revised upwards slightly from previous quarter due to strong Q1 data.

Table Of Contents

Latvia Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Operational Risk 13
Industry Forecast 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Latvia 2011-2019) 15
Healthcare Market Forecast 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2011-2019) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2011-2019) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2011-2019) 19
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Latvia 2011-2019) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Latvia 2011-2019) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Latvia 2011-2019) 25
OTC Drug Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Latvia 2011-2019) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Latvia 2013-2019) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Latvia 2013-2019) 30
Key Risks To BMI's Forecast Scenario 30
Macroeconomic Forecasts 32
Economic Analysis 32
Table: GDP By Expenditure (Latvia 2012-2019) 35
Industry Risk Reward Ratings 36
Central And Eastern Europe Risk/Reward Index - Q4 2015 36
Latvia Risk/Reward Index 42
Rewards 42
Risks 42
Market Overview 44
Industry Trends And Developments 46
Epidemiology 46
Table: Leading Causes of Death, 1990-2010 46
Table: New Cases of Cancer, 2004-2010 48
Table: Cumulative Reported Cases of HIV and AIDS, 2000-2010 50
Healthcare Sector 50
Healthcare Sector Funding 51
Healthcare Provision 52
Table: Healthcare Resources (Latvia 2009-2014) 52
Table: Hospitals and Beds, 2006-2010 53
Table: Hospital Beds by Specialty, 2004-2010 53
Table: Healthcare Personnel (Latvia 2009-2014) 54
Table: Healthcare Activity (Latvia 2009-2014) 55
Research and Development 55
Biotechnology 56
Clinical Trials 58
Regulatory Development 59
Regional Collaboration 60
Intellectual Property 61
Pricing Regime 61
Reimbursement Regime 63
Competitive Landscape 65
Research-Based Industry 65
Table: Licences Issued To Companies Engaged In Pharmaceutical Manufacturing And Distribution, 2007-2011 65
Table: Medicines Consumption According To Marketing Authorisation Holders (turnover in LVL) 66
Generic Drugmakers 67
Pharmaceutical Distribution 67
Table: Wholesale Mark-Up Scheme For Reimbursable Pharmaceuticals, 2008 68
Table: Wholesalers Market Share, 2010 (%) 70
Pharmaceutical Retail Sector 70
Table: Pharmacy Mark-Up Scheme For Reimbursable Pharmaceuticals, 2008 71
Table: Licences Issued To Pharmacies 72
Company Profile 74
GlaxoSmithKline 74
Grindeks 77
Merck and Co 81
Novartis 83
Olainfarm 85
Pfizer 89
Sanofi 91
Demographic Forecast 93
Table: Population Headline Indicators (Latvia 1990-2025) 94
Table: Key Population Ratios (Latvia 1990-2025) 94
Table: Urban/Rural Population and Life Expectancy (Latvia 1990-2025) 95
Table: Population By Age Group (Latvia 1990-2025) 95
Table: Population By Age Group % (Latvia 1990-2025) 96
Glossary 98
Methodology 100
Pharmaceutical Expenditure Forecast Model 100
Healthcare Expenditure Forecast Model 100
Notes On Methodology 101
Risk/Reward Index Methodology 102
Index Overview 103
Table: Pharmaceutical Risk/Reward Index Indicators 103
Indicator Weightings 104

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

  • $ 6 995
  • Industry report
  • February 2016
  • by GBI Research

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes Summary The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 ...

Opportunity in the Indian Pharmaceutical Market - 2016; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

Opportunity in the Indian Pharmaceutical Market - 2016; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

  • $ 5 750
  • Industry report
  • April 2016
  • by Feedback Business Consulting

This report provides an insight into the Indian Pharmaceutical current market scenario, structure and practices. In depth market scenario includes; - Current market size estimates, including domestic market, ...

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

  • $ 5 250
  • Industry report
  • February 2016
  • by Industry ARC

Omega-3 fatty acids are polyunsaturated fatty acids which have potential health benefits and are essential for increasing metabolic rate. Omega-3 PUFA ingredients are used to manufacture products that ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.